Rxrx stock forecast.

Fabrinet (FN) Source: Shutterstock. Fabrinet (NYSE: FN) specializes in the standardized manufacturing of electronic and technical subcomponents. The subcomponents are then sold to companies like ...

Rxrx stock forecast. Things To Know About Rxrx stock forecast.

View live Recursion Pharmaceuticals, Inc. chart to track its stock's price action. Find market predictions, RXRX financials and market news.2013. 550. Chris Gibson. https://www.recursion.com. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which ...Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.Recursion Pharmaceuticals Stock Chart and Share Price Forecast, Short-Term "RXRX" Stock Prediction for Next Days and Weeks Walletinvestor.com Recursion Pharmaceuticals Inc (RXRX) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024

60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making great progress lately in being able to advance its pipeline. That's because it has been advancing two clinical candidates in phase 2 ...Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET.

But the potential upside remains huge. Our roundtable group dug into her holdings and found three stocks that we particularly like. Here's why we're bullish on 10x Genomics ( TXG 2.96%), Beam ...

See Recursion Pharmaceuticals, Inc. (RXRX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.(See RXRX stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy , a newly launched tool that unites all of TipRanks’ equity insights.Zillow is worth $8.3 billion right now, so if it reaches its 2025 sales estimate and continues to grow thereafter, it should breeze past a $10 billion valuation by 2030. 2. Duolingo: Potential ...Nov 7, 2023 · Analyst projections state that RXRX is forecast to be at a low of $9.00 and a high of $35.00. In order for the stock price to hit the forecast high, the stock would need to plunge -532.91% from its current level, while the stock would need to crash -62.75% from its current level to reach the projected low.

Zillow is worth $8.3 billion right now, so if it reaches its 2025 sales estimate and continues to grow thereafter, it should breeze past a $10 billion valuation by 2030. 2. Duolingo: Potential ...

Analyst projections state that RXRX is forecast to be at a low of $9.00 and a high of $35.00. In order for the stock price to hit the forecast high, the stock would need to plunge -532.91% from its current level, while the stock would need to crash -62.75% from its current level to reach the projected low.

Recursion's shares have rallied 191.5% in the past three months compared with the industry’s 0.1% growth. The steep rise in the stock price can also be attributed to RXRX’s recent ...Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Fabrinet (FN) Source: Shutterstock. Fabrinet (NYSE: FN) specializes in the standardized manufacturing of electronic and technical subcomponents. The subcomponents are then sold to companies like ...After announcing that it would get a $50 million investment from NVIDIA ( NVDA 0.67%) on July 12, Recursion Pharmaceuticals ( RXRX 0.43%) saw its stock blast off, rising 87% over the following two ...(See RXRX stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy , a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst.NVDA stock has risen 3% in July, outperforming the Nasdaq Index, and has surged 200% this year, ... RXRX). The biotech company’s stock surged over 120% following the announcement, ...

Both companies could tap into huge growth from the AI revolution in a few years. Schrödinger ( SDGR 2.90%) and Recursion Pharmaceuticals ( RXRX 4.40%) are both biotechs that want to use AI to ...Analyst Future Growth Forecasts. Earnings vs Savings Rate: RXRX is forecast to remain unprofitable over the next 3 years. Earnings vs Market: RXRX is …View the latest Recursion Pharmaceuticals Inc. (RXRX) stock price, news, historical charts, analyst ratings and financial information from WSJ.See Recursion Pharmaceuticals, Inc. (RXRX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET.

Complete Recursion Pharmaceuticals Inc. stock information by Barron's. View real-time RXRX stock price and news, along with industry-best analysis.Find the latest Vacasa, Inc. (VCSA) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W. Mid Term ...

Nov 29, 2023 · Should You Buy or Sell Recursion Pharmaceuticals Stock? Get The Latest RXRX Stock Analysis, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat. Taken together with their deep financial resources, Eli Lilly is one of the best positioned companies to take advantage of the AI-biotech trend. Because Eli Lilly’s future is built off a very ...Forecast . Price target. 15.71 0.00 0.00%. The 7 analysts offering 1 year price forecasts for RXRX have a max estimate of — and a min estimate of —. Analyst rating. Based on 7 analysts giving stock ratings to RXRX in the past 3 months. EPS. Annual Annual Quarterly Quarterly More More(See RXRX stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.RXRX Quantitative Stock Analysis - Benjamin Graham. November 18, 2023 — 01:00 pm EST. Written by John Reese for Validea ->. Below is Validea's guru fundamental report for RECURSION ...Gil Blum, an analyst from Needham, reiterated the Buy rating on Recursion Pharmaceuticals (RXRX – Research Report). The associated price target is $15.00. Gil Blum’s Buy rating for Recursion ...The US$14.13 analyst price target for RXRX is 3.5% less than our ... we will estimate the stock's intrinsic value by taking the forecast future cash flows of the company and discounting ...July 12 (Reuters) - Chip designer Nvidia (NVDA.O) will invest $50 million to speed up training of Recursion's (RXRX.O) artificial intelligence models for drug discovery, the companies said on ...Nov 29, 2023 · Should You Buy or Sell Recursion Pharmaceuticals Stock? Get The Latest RXRX Stock Analysis, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.

The exchange reported a loss of $2.43 per share, compared to forecasts of a $2.52 loss per share, according to the FactSet consensus. Revenue plummeted 75% to $629.1 million, but still beat ...

RXRX Quantitative Stock Analysis - Benjamin Graham. November 18, 2023 — 01:00 pm EST. Written by John Reese for Validea ->. Below is Validea's guru fundamental report for RECURSION ...

You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.4.31%. €8.59M. RXRX | Complete Recursion Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.What's going on at Recursion Pharmaceuticals (NASDAQ:RXRX)? Read today's RXRX news from trusted media outlets at MarketBeat. Skip to main content. S&P 500 4,594.63 (+0.59%) DOW 36,245.50 (+0.82%) ... Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings …Three Fool.com healthcare contributors like Vertex Pharmaceuticals ( VRTX 0.22%), Repligen ( RGEN -2.06%), and Recursion Pharmaceuticals ( RXRX -0.69%). Here's why they believe these three stocks ...Recursion Pharmaceuticals, Inc. Analyst Report: Pfizer Inc. Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales ...You can view all of the due diligence checks on RXRX's stock page. How is RXRX stock valued? You can. use many financial metrics, analyses, models, and charts to gauge RXRX's intrinsic value.Using relative valuations . metrics:RXRX; could be undervalued based on its P/B ratio of 3.35x, relative to Biotechnology industry P/B ratio of . 5.36xRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making great progress lately in being able to advance its pipeline. That's because it has been advancing two clinical candidates in phase 2 ...Jul 28, 2023 · RXRX Stock Performance on July 28, 2023: Decrease in Price and Analyst Forecasts. RXRX stock performance on July 28, 2023, showed a decrease from the previous price. The 12-month price forecasts for Recursion Pharmaceuticals Inc provided by 8 analysts had a median target of 12.50, with a high estimate of 35.00 and a low estimate of 9.00.

Ticker Symbol: RXRX: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: IPO Price: $18.00: CIK Code: 0001601830: CUSIP Number: 75629V104 ...About the Recursion Pharmaceuticals, Inc. Class A Common Stock stock forecast. As of 2023 December 02, Saturday current price of RXRX stock is 6.910$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Recursion Pharmaceuticals stock price has been showing a declining tendency so we …NVIDIA Corporation Common Stock. $416.10 +5.93 +1.45%. ARM. Arm Holdings plc American Depositary Shares. $51.32 -0.84 -1.61%. Find the latest analyst research for Recursion Pharmaceuticals, Inc ...Instagram:https://instagram. highest yield bond10 cent stock3x short dowforex mexico Analyst Future Growth Forecasts. Earnings vs Savings Rate: RXRX is forecast to remain unprofitable over the next 3 years. Earnings vs Market: RXRX is …Now's a great time to invest in biotechs that have AI as a tailwind. Ginkgo Bioworks uses AI to run bioengineering projects for other biotechs. Recursion Pharmaceuticals uses AI to find good leads ... best investment advisory servicesbest sep plans Complete Recursion Pharmaceuticals Inc. stock information by Barron's. View real-time RXRX stock price and news, along with industry-best analysis.The Recursion Pharmaceuticals, Inc. stock price gained 7.88% on the last trading day (Friday, 1st Dec 2023), rising from $6.85 to $7.39. During the last trading day … best credit card for military personnel 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share.Jul 28, 2023 · RXRX Stock Performance on July 28, 2023: Decrease in Price and Analyst Forecasts. RXRX stock performance on July 28, 2023, showed a decrease from the previous price. The 12-month price forecasts for Recursion Pharmaceuticals Inc provided by 8 analysts had a median target of 12.50, with a high estimate of 35.00 and a low estimate of 9.00. The Recursion Pharmaceuticals, Inc. stock price gained 1.18% on the last trading day (Friday, 24th Nov 2023), rising from $6.78 to $6.86. During the last trading day the stock fluctuated 5.06% from a day low at $6.71 to a day high of $7.05. The price has risen in 7 of the last 10 days and is up by 31.17% over the past 2 weeks.